The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana

Journal of Acquired Immune Deficiency Syndromes

Volumn 49, Issue 2, 2008, Pages 227-229

  Bisson, Gregory P ^a   Nthobatsong, Rudo ^a   Thakur, Rameshwari ^a   Lesetedi, Gloria ^a   Vinekar, Kavita ^a   Tebas, Pablo ^a   Bennett, John E ^b   Gluckman, Stephen ^a   Gaolathe, Tendani ^c   MacGregor, Rob R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c Infectious Disease Care Clinic   (Botswana)

Author keywords

Africa; Cohort study; Cryptococcal meningitis; HAART

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIRETROVIRUS AGENT; FLUCONAZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CRYPTOCOCCAL MENINGITIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK; SEX; SURVIVAL; TUBERCULOSIS; COHORT ANALYSIS; COMPARATIVE STUDY; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BOTSWANA; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; LOGISTIC MODELS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 55249115992     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318183181e     Document Type: Article

References (8)

1. Jenny-Avital ER, Abadi M. Immune reconstitution cryptococcosis after initiation of successful highly active antiretroviral therapy. Clin Infect Dis. 2002;35:e128-e133.
2. Shelburne SA III, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:1049-1052.
3. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIVassociated cryptococcosis in France. AIDS. 2005;19:1043-1049.
4. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS. 2005;19:2050-2052.
5. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30:710-718.
6. Cepeda MS, Boston R, Farrar JT, et al. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol. 2003;158:280-287.
7. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal. meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis. 2007;45:76-80.
8. Siddiqui AA, Brouwer AE, Wuthiekanun V, et al. IFN-gamma at the site of infection determines rate of clearance of infection in cryptococcal meningitis. J Immunol. 2005;174:1746-1750.